[REVISION HISTORY]

Quantum BioPharma MS therapy development

Updated 3 times since CLSTR started tracking revisions of this situation.

What changed

2026-08-13 01:50 UTC → 2026-08-31 19:01 UTC · added ~~removed~~

In July 2026, Quantum BioPharma announced that its proprietary multiple‑sclerosis candidate LUCID‑MS had completed Phase 1 studies in healthy volunteers with a favorable safety profile and had filed an IND with the U.S. FDA, clearing the way for patient‑focused Phase 2 trials. By early August 2026, the company reported that a pilot imaging study conducted with Massachusetts General Hospital had reached the midpoint of patient enrollment. The PET‑based scans showed promising signals in acute MS lesions, providing a potential biomarker that could accelerate evaluation of LUCID‑MS and other remyelinating therapies. ~~This novel PET imaging technique can differentiate between viable demyelinated nerve fibers and permanently damaged axons.~~ On August 10, 2026, the FDA approved the Investigational New Drug application for LUCID-MS (Lucid-21-302), officially allowing the candidate to proceed to Phase 2 clinical development. Unlike existing therapies that focus on immune system modulation to reduce inflammation, LUCID-MS aims to provide neuroprotection by targeting the protein arginine deiminase 2 (PAD2) enzyme. This mechanism is intended to inhibit demyelination, which preclinical models suggest could prevent or even reverse myelin breakdown. The upcoming Phase 2 study will be a randomized, double-blind, placebo-controlled trial evaluating efficacy, safety, and tolerability through clinical and radiological measures. Quantum BioPharma is currently working with a clinical research organization to support the trial and is in the process of site selection to begin patient enrollment and dosing. On August 31, 2026, Rodman & Renshaw initiated coverage on Quantum BioPharma Ltd. with a ‘Buy’ rating and an $8.00 price target. The rating was attributed to the potential of the LUCID-MS candidate, which is being developed through the company’s subsidiary, Lucid Psycheceuticals Inc., as a patented non-immunomodulatory small molecule designed to address neurodegeneration and disability progression in progressive multiple sclerosis.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.